Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | PDE6D | O43924 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170869 | 1.00 | HMGCR (0.78) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4209321 | 1.00 | HMGCR (0.78) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3070830 | 1.00 | HMGCR (0.78) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10305921 | 0.93 | HMGCR (0.73) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3198400 | 0.93 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3201932 | 0.93 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3210158 | 0.93 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL5316885 | 0.93 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3201954 | 0.93 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10297391 | 0.93 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701642-B2 | Method for producing optically active 5-hydroxy-3-ketoester | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-11 | — | — | US | claimed |
| US-20160185734-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-06-30 | — | — | US | claimed |
| US-20170305867-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | API CORPORATION (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9701642-B2 | Method for producing optically active 5-hydroxy-3-ketoester | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9695130-B2 | Rosuvastatin calcium and process for producing intermediate thereof | API CORPORATION (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160347718-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | API CORPORATION (JP) | 2016-12-01 | — | — | US | disclosed |
| EP-1912953-B1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS (SI) | 2016-08-17 | — | — | EP | disclosed |
| US-20160185734-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-06-30 | — | — | US | disclosed |
| US-8354530-B2 | Preparation of HMG-CoA reductase inhibitors, in particular rosuvastatin calcium, introducing L-malic acid as source of chirality for side chain; statin core moiety is consecutively coupled with chiral segment containing 4 carbon atoms and segment containing 2 carbon atoms; treating hypercholesterolemia | Lek Pharmaceuticals d. d (SI) | 2013-01-15 | — | — | US | disclosed |
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-20090312547-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION | AUROBINDO PHARMA LTD (IN) | 2009-12-17 | — | — | US | disclosed |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2009-05-14 | — | — | US | disclosed |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | LEK PHARMACEUTICALS D.D (SI) | 2008-10-16 | — | — | US | disclosed |
| US-20080161560-A1 | Process for Preparation of Calcium Salt of Rosuvastatin | DESHPANDE PANDURANG BALWANT | 2008-07-03 | — | — | US | disclosed |
| EP-1912953-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK Pharmaceuticals D.D. (SI) | 2008-04-23 | — | — | EP | disclosed |
| EP-1869005-A1 | PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2007-12-26 | — | — | EP | disclosed |
| EP-1863773-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007017117-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS D.D. (SI) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006106526-A1 | PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006100689-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185734-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER | CYP51A1, HSD3B1, CYP3A5 | HMGCR 74/4885ALDH1A1 265/4885CYP3A4 25/4885 |
| US-20090312547-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION | CACNA1C, CACNG5, CACNA1A | HMGCR 18/4885ALDH1A1 2101/4885CYP3A4 607/4885 |
| US-20160347718-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | HMGCR, COASY, PCSK9 | HMGCR 1/4885ALDH1A1 2111/4885CYP3A4 163/4885 |
| US-20170305867-A1 | ROSUVASTATIN CALCIUM AND PROCESS FOR PRODUCING INTERMEDIATE THEREOF | HMGCR, COASY, PCSK9 | HMGCR 1/4885ALDH1A1 2111/4885CYP3A4 163/4885 |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | HMGCR, ME1, COASY | HMGCR 1/4885ALDH1A1 1292/4885CYP3A4 151/4885 |
| US-20080161560-A1 | Process for Preparation of Calcium Salt of Rosuvastatin | CACNA1C, CACNA1E, CACNA1S | HMGCR 16/4885ALDH1A1 2901/4885CYP3A4 583/4885 |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | ACSL5, HMGCR, PCSK9 | HMGCR 2/4885ALDH1A1 1776/4885CYP3A4 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.